Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC Amezalpat builds ...

Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...

Dr. Waqqas Tai is a cancer doctor who often shares health advice online. He recently revealed what the five most "lethal" ...

A cancer expert has shared the five types of cancer which are considered the most "lethal", and claimed people diagnosed with ...

Tempest Therapeutics (TPST) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track Designation, FTD, to amezalpat, ...

CAR T-cell therapies have demonstrated efficacy in treating blood cancers but, so far, their safety and effectiveness in ...

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small ...

Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and growth potential. Learn why BMY stock is a solid ...

CSL Behring's gene therapy Hemgenix four years post-infusion data continue to show sustained efficacy and safety in adults with haemophilia B: King of Prussia, Pennsylvania Monday ...

Non-communicable diseases rank among the most serious global health challenges of the 21st century due to their high prevalence and substantial socioeconomic and health-care impact. According to WHO, ...

Shares of solid tumor concern Zymeworks Inc. have barely budged since the company obtained its first approval. Click here to read why ZYME stock is a Hold.